Abbott - Model TriClip™ -Transcatheter Tricuspid Valve Repair System
The TriClip™ Transcatheter Tricuspid Valve Repair System, developed by Abbott, is specifically designed for the minimally invasive treatment of severe tricuspid regurgitation (TR), particularly in patients who face high surgical risks. This device provides a transcatheter edge-to-edge repair (TEER) approach, leveraging proven leaflet repair technology to achieve consistent reduction in TR. It offers stable navigation and precise delivery, supported by an intuitive design that simplifies handling and deployment. The system includes innovative components such as a delivery catheter handle, arm positioner, and a guide attachment braking system, all engineered to enhance safety and efficacy. It is distinct in its focus on the tricuspid valve, providing a critical, less-invasive alternative for improving patients' quality of life and reducing heart failure hospitalizations when compared to traditional medical therapy. The system is available in multiple implant sizes to cater to patient-specific anatomical needs.
TriClip™ Transcatheter Edge-to-Edge Repair (TEER) offers a minimally invasive treatment option for patients with symptomatic, severe tricuspid regurgitation (TR) who are at high risk for surgery.
The TriClip Transcatheter Edge-to-Edge Repair (TEER) system is the only TEER device intentionally designed for the tricuspid valve. With stable navigation and precise delivery, TriClip TEER is the only tricuspid device proven to reduce risk of heart failure hospitalization and improve quality of life, relative to optimal medical therapy. In both randomized and real-world studies, TriClip TEER has proven:
- Exceptional safety profile
- Maximized effectiveness in tricuspid regurgitation (TR) reduction
- Life Changing Improvements to heart failure hospitalization risk and quality of life
A state-of-the-art treatment option for patients at intermediate or greater risk for surgery
TriClip TEER is a low-risk, non-surgical treatment option for improving quality of life and functional status in patients with symptomatic severe tricuspid regurgitation, despite optimal medical therapy, who are at intermediate or greater risk for surgery and in whom transcatheter edge-to-edge valve repair is clinically appropriate and is expected to reduce tricuspid regurgitation severity to moderate or less, as determined by a multidisciplinary heart team.
- Transcatheter beating heart procedure - no cardiopulmonary bypass
- Allows for real-time positioning and repositioning to optimize TR reduction
- Femoral venous access
- Can be used in a standard cath lab or hybrid room
- No pre-procedural CT required
- Fast recovery times; many patients go home the next day
The TriClip™ G5 Transcatheter Edge-to-Edge Repair System empowers you with stable navigation and precise delivery for complex conditions.
EASY HANDLING
- Quick, secure docking with spring-loaded attachments for easy connection
- Precise locking with binary lock knob to support consistent performance
- Built-in fastener for easy securement of the DC
PRECISE POSITIONING
- New guide attachment with braking system maintains desired positioning for enhanced control
- Controlled movement with redesigned stabilizer rail and handles
- Responsive new handle design capable of delivering 1:1 rotation
INTUITIVE DEPLOYMENT
- New lock knob offers easy and straightforward lock line release and removal
- Hard stop within arm positioner reduces dependence on visual indicators for more control
- Disconnect with ease using new release pin with finger hold to initiate deployment